Cita APA (7a ed.)
Elimova, E., Ajani, J., Burris, H., Denlinger, C. S., Iqbal, S., Yoon-Koo, K., . . . Ku, G. (Jul 2025). Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: Primary results of a multicentre, single-arm, phase 2 study. Lancet Oncology. https://doi.org/10.1016/S1470-2045(25)00287-6
Cita Chicago Style (17a ed.)
Elimova, Elena, et al. "Zanidatamab Plus Chemotherapy as First-line Treatment for Patients with HER2-positive Advanced Gastro-oesophageal Adenocarcinoma: Primary Results of a Multicentre, Single-arm, Phase 2 Study." Lancet Oncology Jul 2025. https://doi.org/10.1016/S1470-2045(25)00287-6.
Cita MLA (9a ed.)
Elimova, Elena, et al. "Zanidatamab Plus Chemotherapy as First-line Treatment for Patients with HER2-positive Advanced Gastro-oesophageal Adenocarcinoma: Primary Results of a Multicentre, Single-arm, Phase 2 Study." Lancet Oncology, Jul 2025, https://doi.org/10.1016/S1470-2045(25)00287-6.
Precaución: Estas citas no son 100% exactas.